MX364946B - Sistema adyuvante mejorado para la administración de vacunas orales. - Google Patents

Sistema adyuvante mejorado para la administración de vacunas orales.

Info

Publication number
MX364946B
MX364946B MX2014011806A MX2014011806A MX364946B MX 364946 B MX364946 B MX 364946B MX 2014011806 A MX2014011806 A MX 2014011806A MX 2014011806 A MX2014011806 A MX 2014011806A MX 364946 B MX364946 B MX 364946B
Authority
MX
Mexico
Prior art keywords
adminstration
adjuvant system
oral vaccine
improved adjuvant
compositions
Prior art date
Application number
MX2014011806A
Other languages
English (en)
Other versions
MX2014011806A (es
Inventor
Morefield Garry
Original Assignee
Vaxform Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxform Llc filed Critical Vaxform Llc
Publication of MX2014011806A publication Critical patent/MX2014011806A/es
Publication of MX364946B publication Critical patent/MX364946B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona composiciones adyuvantes que tienen estabilidad mejorada, potencia incrementada y que proporcionan una respuesta Th1 elevada, y en donde las composiciones pueden administrarse en forma oral. La presente invención también proporciona métodos para elaborar esas composiciones y la administración de las composiciones adyuvantes mejoradas.
MX2014011806A 2012-04-04 2013-04-03 Sistema adyuvante mejorado para la administración de vacunas orales. MX364946B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261686372P 2012-04-04 2012-04-04
PCT/US2013/000102 WO2013151595A1 (en) 2012-04-04 2013-04-03 Improved adjuvant system for oral vaccine adminstration

Publications (2)

Publication Number Publication Date
MX2014011806A MX2014011806A (es) 2015-06-03
MX364946B true MX364946B (es) 2019-05-15

Family

ID=49300897

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011806A MX364946B (es) 2012-04-04 2013-04-03 Sistema adyuvante mejorado para la administración de vacunas orales.

Country Status (10)

Country Link
US (3) US20150079130A1 (es)
EP (2) EP2833914B1 (es)
JP (1) JP6240155B2 (es)
KR (1) KR101867428B1 (es)
AU (1) AU2013243971B2 (es)
CA (1) CA2903313C (es)
DK (1) DK2833914T3 (es)
IL (1) IL234937B (es)
MX (1) MX364946B (es)
WO (1) WO2013151595A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106255508B (zh) * 2014-02-20 2020-07-07 瓦克萨特公司 用于小肠递送的制剂
CA2988165C (en) * 2014-06-20 2023-08-01 University Of Saskatchewan Exotoxin/thermolysin compositions and methods and uses for treating or preventing laminitis
BR112018068057A2 (pt) * 2016-03-07 2019-01-08 Glaxosmithkline Biologicals Sa pluralidade de partículas de dispensação de fármaco sensíveis a ph, composição, frasco, dispositivo para administração parenteral, uso de uma pluralidade de partículas ou de uma composição, métodos para obter uma resposta imune, de tratamento ou profilaxia, para impedir ou reduzir a interação entre uma carga biologicamente ativa e componentes de um ambiente aquoso, para produzir uma pluralidade de partículas de dispensação de fármaco e para produzir uma composição, e, vacina
KR102369740B1 (ko) 2020-09-21 2022-03-02 부경대학교 산학협력단 자궁경부암 조기진단을 위한 모바일 질확대경 장치
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018453A1 (en) * 1996-10-28 1998-05-07 Pfizer Inc. Oral vaccines for young animals with an enteric coating
ATE284613T1 (de) * 1997-02-14 2005-01-15 Merck & Co Inc Polynukleotid-impfstoff-formulierungen
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
US20030162955A1 (en) * 1998-03-17 2003-08-28 Lionel Chalus Isolated mammalian membrane protein genes; related reagents
IL140669A0 (en) * 1998-07-08 2002-02-10 Kirin Amgen Inc Powdery preparation for mucosal administration containing polymeric medicine
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
BR0313650A (pt) * 2002-08-20 2007-08-14 Genitrix Llc composição, vetor de expressão, composição de vacina e uso
WO2004073652A2 (en) * 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP2066348A1 (en) * 2006-09-26 2009-06-10 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
EP2464341B1 (en) * 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
GB0919690D0 (en) * 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions

Also Published As

Publication number Publication date
WO2013151595A1 (en) 2013-10-10
US20150079130A1 (en) 2015-03-19
DK2833914T3 (en) 2019-03-11
JP2015512441A (ja) 2015-04-27
KR101867428B1 (ko) 2018-07-19
CA2903313A1 (en) 2013-10-10
AU2013243971A1 (en) 2014-10-02
AU2013243971B2 (en) 2017-01-05
EP2833914B1 (en) 2019-01-16
KR20150002755A (ko) 2015-01-07
US20210052725A1 (en) 2021-02-25
IL234937A0 (en) 2014-12-31
IL234937B (en) 2021-10-31
MX2014011806A (es) 2015-06-03
EP3549605A1 (en) 2019-10-09
JP6240155B2 (ja) 2017-11-29
CA2903313C (en) 2019-10-22
EP2833914A4 (en) 2016-03-30
US20190105389A1 (en) 2019-04-11
EP2833914A1 (en) 2015-02-11

Similar Documents

Publication Publication Date Title
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2018002301A (es) Composiciones de glucano y usos de las mismas.
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX348823B (es) Formulaciones estables de linaclotida.
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
BR112012029912A2 (pt) vácinas de combinação de nanotransportadores sintéticos
PH12014501991B1 (en) Phenicol antibacterials
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX2015011109A (es) Composiciones estables de activador de glucoquinasa.
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
IN2013MU01177A (es)
EP3326628A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH HIGH-CONCENTRATED TAXAN
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
IN2013MU03422A (es)
WO2014122671A3 (en) Solid oral compositions of saxagliptin
IN2013MU03309A (es)

Legal Events

Date Code Title Description
FG Grant or registration